z-logo
open-access-imgOpen Access
Monoclonal Gammopathy in Chronic Lymphocytic Leukemia: A Case Report and Review of its Literature
Author(s) -
Vasu Babu Goli,
Ronak Jain,
Ganapathi Bhat,
A Sainani,
SH Advani
Publication year - 2018
Publication title -
indian journal of medical and paediatric oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.229
H-Index - 22
eISSN - 0975-2129
pISSN - 0971-5851
DOI - 10.4103/ijmpo.ijmpo_129_17
Subject(s) - chronic lymphocytic leukemia , monoclonal , medicine , monoclonal antibody , clone (java method) , immunology , immunofixation , gammopathy , leukemia , monoclonal gammopathy of undetermined significance , pathology , antibody , biology , dna , genetics
The presence of monoclonal gammopathies in B-cell malignancies occurs frequently. Monoclonal proteins are present in a significant number of patients with chronic lymphocytic leukemia (CLL), which is a disorder of antigen-stimulated mature B-cells. The recognition of monoclonal proteins or light chains in the serum and/or urine is increased in the majority of CLL patients with the use of highly sensitive laboratory methods such as serum immunofixation studies. A different autoimmune phenomenon may explain the presence of some of these monoclonal proteins. Some reports indicate that the finding of monoclonal proteins has a negative impact on patients' survival. However, there is no clear evidence to suggest the prognostic significance of monoclonal proteins in patients with CLL. Although the presence of monoclonal proteins in CLL occurs usually at an incidence of 60%–80%, there are very few cases reported in literature. We report a case of CLL diagnosed in 2009 who developed disease progression along with the presence of immunoglobulin kappa monoclonal gammopathy. Although the presence of monoclonal gammopathy might be due to the use of highly sensitive methods, this can be due to autoimmune phenomenon or development from the same or different clone of B-cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here